- Latest available (Revised)
- Point in Time (31/12/2020)
- Original (As made)
Point in time view as at 31/12/2020.
The Human Medicines Regulations 2012, PART 9 is up to date with all changes known to be in force on or before 31 August 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
159.—(1) This regulation applies if the licensing authority thinks that a product without a [F1UK] marketing authorisation, traditional herbal registration, certificate of registration or [F2, only in relation to a product for sale or supply in Northern Ireland, an Article 126a authorisation or an EU marketing authorisation,] is a medicinal product.
(2) The licensing authority may give a notice in writing (a “provisional determination notice”) to any person (the “recipient”)—
(a)who has sold or supplied the product, or has offered to sell or supply it; or
(b)whom the licensing authority thinks may sell or supply the product.
(3) The provisional determination notice must—
(a)advise the recipient that the licensing authority has made a provisional determination that the product is a medicinal product;
(b)give reasons for the provisional determination;
(c)advise the recipient of the recipient's rights to challenge the provisional determination in accordance with regulation 160 and
(d)specify a period of at least six weeks beginning immediately after the date on which the provisional determination notice is given to the recipient (in this Part “the determination date”) within which any written representations in accordance with regulation 160(2)(a) must be made to the licensing authority.
Textual Amendments
F1Word in reg. 159(1) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 133(a); 2020 c. 1, Sch. 5 para. 1(1)
F2Words in reg. 159(1) substituted (31.12.2020) by virtue of S.I. 2019/775, reg. 133(b) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 100)
160.—(1) A recipient of a provisional determination notice may, within the period of four weeks beginning immediately after the determination date, give notice in writing to the licensing authority requesting the authority to submit the provisional determination to review.
(2) If the recipient gives such notice the recipient must—
(a)within the period specified in the provisional determination notice, make written representations to the licensing authority explaining why the recipient thinks the product is not a medicinal product; or
(b)within the period of four weeks beginning immediately after the determination date, inform the licensing authority in writing that the recipient wants to make oral representations explaining why the recipient thinks the product is not a medicinal product.
(3) If—
(a)the recipient has informed the licensing authority that the recipient wants to make written representations in accordance with paragraph (2)(a); and
(b)the licensing authority thinks that, because of exceptional circumstances or the nature or complexity of the issues involved, additional time is needed for the preparation of written representations,
the licensing authority may alter the period for making written representations.
(4) The licensing authority must inform the recipient in writing of an alteration under paragraph (3) and of the reasons for it.
161.—(1) If a recipient makes written representations in accordance with regulation 160(2)(a) the licensing authority must appoint a panel of at least two persons (“the reviewers”) to advise on the provisional determination.
(2) The licensing authority must provide the reviewers with—
(a)the recipient's written representations; and
(b)any written representations of the licensing authority.
(3) The reviewers must advise the licensing authority on the authority's provisional determination taking account of—
(a)the written representations; and
(b)any other evidence submitted to them.
(4) The licensing authority must take into account the reviewers' advice and make a final determination as to whether the product is a medicinal product.
(5) The licensing authority must—
(a)inform the recipient in writing of its final determination and of the reasons for it; and
(b)if the licensing authority disagrees with the reviewers' advice, inform the recipient in writing of the reasons for that disagreement.
162.—(1) If a recipient informs the licensing authority in accordance with regulation 160(2)(b) that the recipient wants to make oral representations, the licensing authority must—
(a)appoint a panel of at least two persons (“the reviewers”) to conduct the review; and
(b)after consultation with the recipient set a date for the hearing.
(2) The licensing authority may alter the date of the hearing at the request of the recipient or of its own motion if it thinks that because of exceptional circumstances or the nature or complexity of the issues involved additional time is needed for preparation for the hearing.
(3) The licensing authority must inform the recipient in writing of any alteration under paragraph (2) and of the reasons for it.
(4) The recipient and the licensing authority may make oral representations at the hearing.
(5) The reviewers must advise the licensing authority on the authority's provisional determination, taking account of—
(a)the oral representations made and any other evidence submitted by the recipient at the hearing;
(b)any oral representations made or other evidence submitted by the licensing authority at the hearing; and
(c)any other evidence heard by the review panel.
(6) The licensing authority must take into account the reviewers' advice and make a final determination as to whether the product is a medicinal product.
(7) The licensing authority must—
(a)inform the recipient in writing of its final determination and of the reasons for it; and
(b)if the licensing authority disagrees with the reviewers' advice, inform the recipient in writing of the reasons for that disagreement.
163.—(1) This regulation applies if the recipient—
(a)does not give notification to the licensing authority that the recipient wishes to challenge its provisional determination within the period of four weeks beginning immediately after the determination date;
(b)gives such notification, but fails to make written representations to the licensing authority within the period for making those representations; or
(c)gives such notification, but fails to make oral representations at a hearing before the reviewers appointed for the purposes of advising on the provisional determination.
(2) The licensing authority must—
(a)make a final determination as to whether the product is a medicinal product; and
(b)inform the recipient in writing of its final determination and of the reasons for it.
164.—(1) If the licensing authority makes a final determination that a product is a medicinal product, it may give a notice to any person—
(a)who has sold or supplied the product, or has offered to sell or supply it; or
(b)whom the licensing authority thinks may sell or supply the product.
(2) The notice must require the person—
(a)to cease to sell, supply or offer to sell or supply the product from the date specified in the notice until a [F3UK] marketing authorisation, traditional herbal registration, certificate of registration or [F4, only in relation to a product for sale or supply in Northern Ireland, an Article 126a authorisation or an EU marketing authorisation,] is granted in respect of the product; or
(b)not to sell, supply or offer to sell or supply the product unless a [F5UK] marketing authorisation, traditional herbal registration, certificate of registration or [F6, only in relation to a product for sale or supply in Northern Ireland, an Article 126a authorisation or an EU marketing authorisation,] is granted in respect of the product.
Textual Amendments
F3Word in reg. 164(2)(a) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 134(a); 2020 c. 1, Sch. 5 para. 1(1)
F4Words in reg. 164(2)(a) substituted (31.12.2020) by S.I. 2019/775, reg. 134(b) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 101)
F5Word in reg. 164(2)(b) inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 134(a); 2020 c. 1, Sch. 5 para. 1(1)
F6Words in reg. 164(2)(b) substituted (31.12.2020) by virtue of S.I. 2019/775, reg. 134(b) (as substituted by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 101)
165. Nothing in this Part prevents the licensing authority from determining that a product is a medicinal product [F7in relation to these Regulations] without following the procedures in this Part when it thinks it appropriate.
Textual Amendments
F7Words in reg. 165 inserted (E.W.S.) (31.3.2014) by The Human Medicines (Amendment) Regulations 2014 (S.I. 2014/490), regs. 1(2), 3 and words in reg. 165 inserted (N.I.) (31.3.2014) by The Human Medicines (Amendment) Regulations 2014 (S.R. 2014/323), regs. 1(2), 3
166.—(1) A person is guilty of an offence if that person sells or supplies, or offers to sell or supply a product in breach of a notice under regulation 164(1) imposing a requirement under—
(a)regulation 164(2)(a); or
(b)regulation 164(2)(b).
(2) A person guilty of an offence under this regulation is liable—
(a)on summary conviction to a fine not exceeding the statutory maximum; or
(b)on conviction on indictment, to a fine, to imprisonment for a term not exceeding two years or to both.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: